Economic evaluations of olanzapine and risperidone.
Shaw
James W
JW
Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, The University of Arizona, Tucson 85721-0207, USA. shaw@pharmacy.arizona.edu
D014150:Antipsychotic Agents / Q000191:economics* / Q000627:therapeutic use; D001569:Benzodiazepines; D003362:Cost-Benefit Analysis; D006801:Humans; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D018967:Risperidone / Q000191:economics* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy / Q000191:economics
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D018967:Risperidone; D000077152:Olanzapine